GILD vs. SNY: Gilead Sciences vs. Sanofi Stock Comparison

Company Profile

Gilead Sciences (GILD) and Sanofi (SNY) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but GILD is classified in Biotechnology while SNY is classified in Pharmaceuticals.

Gilead Sciences (GILD) trades as ordinary local shares, while Sanofi (SNY) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Gilead Sciences (GILD) reports a negative ROE of -22.45%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Sanofi (SNY) reports 5.72%, ranking against industry peers normally.

Gilead Sciences (GILD) reports a negative net margin of -12.46%, usually indicating a net loss over the period. Meanwhile Sanofi (SNY) reports 8.20%, ranking against industry peers normally.

Both Gilead Sciences (GILD) at 42.43% and Sanofi (SNY) at 30.89% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Both Gilead Sciences (GILD) at 2.39% and Sanofi (SNY) at 5.49% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Gilead Sciences (GILD) at 1,684.21% clears its industry range for EPS growth, a much stronger earnings trajectory than Sanofi (SNY) at 39.43%, which is closer to a typical peer reading.

Growth Metrics

Financial Strength

Both Gilead Sciences (GILD) at 1.38 and Sanofi (SNY) at 1.12 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

Sanofi (SNY) at 0.27 is near its industry mid-range for debt-to-equity ratio, while Gilead Sciences (GILD) at 2.02 sits above its benchmark range, pointing to a heavier debt load relative to equity.

Financial Strength Metrics

Dividends

Sanofi (SNY) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Gilead Sciences (GILD) reports a yield of 1.94%, ranking against industry peers normally.

Sanofi (SNY) reports payout ratio above 100% at 119.86%, meaning dividends exceeded current-period earnings and sustainability needs extra context. Meanwhile Gilead Sciences (GILD) reports 43.46%, ranking against industry peers normally.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: Sanofi (SNY) trades at 23.40 times trailing earnings, ranked against its peers, while Gilead Sciences (GILD) has no P/E ratio this period.

Sanofi (SNY) at 2.21 sits in the cheaper P/S ratio quartile while Gilead Sciences (GILD) at 6.68 prices around its industry’s middle — SNY costs less per dollar of sales, though read it alongside growth and margins.

Sanofi (SNY) at 1.38 sits in the lower P/B ratio quartile relative to book while Gilead Sciences (GILD) at 15.88 prices above its industry range — a wide valuation gap against assets.

Valuation Metrics